

Announcements

A Syllabus of Thalassemia Mutations

In collaboration with Dr. Erol Baysal, Dubai, United Arab Emirates, we have prepared an extensive compendium, titled *A Syllabus of Thalassemia Mutations (1997)*, that lists data for each of nearly 200 β -thalassemia alleles (including approximately 20 deletions), the 17 δ -thalassemia and one γ -thalassemia alleles, 14 nondeletional and seven deletional hereditary persistence of fetal hemoglobin determinants, the more than 30 $\delta\beta$ -thalassemia (including $^A\gamma\delta\beta$ - and $\epsilon\gamma\delta\beta$ -thalassemia) determinants, as well as the 32 nondeletional and eight deletional α -thalassemia-2 and 25 deletional α -thalassemia-1 alleles. Frequency data are reviewed in numerous tables and special sections on the Swiss type of hereditary persistence of fetal hemoglobin and Hb H disease are provided.

The *Syllabus* will be available for distribution in the summer of 1997 at a cost of US \$50.00/copy plus \$5.00 shipping and handling for domestic first class mail, and \$15.00 shipping and handling for foreign air mail. Checks, money orders, or purchase orders should be made payable to the Sickle Cell Anemia Foundation. Please send your order (which must include your name and complete mailing address, telephone and FAX numbers) to Professor Dr. Titus H.J. Huisman, Research & Education Building, Room CB-2208, Medical College of Georgia, Augusta, GA 30912-2100 (USA).

Research & Education Building
Room CB-2208

T.H.J. Huisman
M.F.H. Carver

Medical College of Georgia
Augusta, GA 30912-2114, USA
Tel: 706-721-3091
Fax: 706-721-3092

Venisect, Inc. Changes Name to TRANSMEDICA™

Little Rock, July 31, 1997—Venisect, Inc. has changed its corporate name to TRANSMEDICA INTERNATIONAL, INC., effective immediately. The company's Laser Lancet® will continue to be marketed under its registered trademark name.

TRANSMEDICA's President and Chief Executive Officer, Charles H. Vestal, said "We believe that our new corporate name more accurately signifies the range of products and services the company may offer."

TRANSMEDICA is a privately held company with headquarters offices in Little Rock, AR.

The company has received Food and Drug Administration clearance to market its Laser Lancet®, a medical laser used for capillary blood sampling among healthy adults. The device is manufactured for TRANSMEDICA by LaBarge, Inc. (L3-AMEX) which is headquartered in St. Louis, MO.

For more information:

J. Craig Barnes
Vice President, Communications
501-376-3938 888-992-5305 (Pager)